Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Kathy S. Albain, Laura J. Esserman, Constantine Godellas et al.|Clinical Cancer Research|2023

Cited by 20